Cannabis pharmaceutical BDS Analytics

As more U.S. states move towards legalization, cannabis consumers are taking advantage of the unique opportunity to address medical needs through the available products at their local dispensaries. Though medical cannabis is generally not covered by most U.S. insurance plans, trends indicate increased use of cannabis as an alternative to more traditional forms of medication.…

Read More
pharmaceuticals vs dispensaries | BDS Analytics

Epidiolex Approval Queues Up Pharmaceutical Versus Dispensary Cannabinoids Competition Pharmaceutical cannabinoids have been around since the 1980s in synthetic or semi-synthetic form for the treatment of nausea related to cancer, and anorexia related to both cancer and AIDS. The FDA approved GW Pharmaceuticals’ Epidiolex in 2018 marking the first time that the US federal government…

Read More